Literature DB >> 21371842

PET/CT and vascular disease: current concepts.

José Leite Gondim Cavalcanti Filho1, Ronaldo de Souza Leão Lima, Luiz de Souza Machado Neto, Leonardo Kayat Bittencourt, Romeu Côrtes Domingues, Lea Mirian Barbosa da Fonseca.   

Abstract

Since its introduction in 2001, positron emission tomography associated to computed tomography (PET/CT) has been established as a standard tool in cancer evaluation. Being a multimodality imaging method, it combines in a single session the sensitivity granted by PET for detection of molecular targets within the picomolar range, with an underlying submilimetric resolution inherent to CT, that can precisely localize the PET findings. In this last decade, there have been new insights regarding the pathophysiology of atherosclerosis, particularly about plaque rupture and vascular remodeling. This has increased the interest for research on PET/CT in vascular diseases as a potential new diagnostic tool, since some PET molecular targets could identify diseases before the manifestation of gross anatomic features. In this review, we will describe the current applications of PET/CT in vascular diseases, emphasizing its usefulness in the settings of vasculitis, aneurysms, vascular graft infection, aortic dissection, and atherosclerosis/plaque vulnerability. Although not being properly peripheral vascular conditions, ischemic cardiovascular disease and cerebrovascular disease will be briefly addressed as well, due to their widespread prevalence and importance.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21371842     DOI: 10.1016/j.ejrad.2010.12.102

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  8 in total

1.  The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.

Authors:  Gabriella Moroni; Massimo Castellani; Aurora Balzani; Roberto Dore; Nicola Bonelli; Selena Longhi; Isabella Martinelli; Piergiorgio Messa; Paolo Gerundini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

2.  Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?

Authors:  F B van Hoeij; R G M Keijsers; B C A J Loffeld; G Dun; P H G M Stadhouders; B L A M Weusten
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-20       Impact factor: 9.236

3.  Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105.

Authors:  Hakan Orbay; Hao Hong; Jill M Koch; Hector F Valdovinos; Timothy A Hacker; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

4.  Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105.

Authors:  Hakan Orbay; Yin Zhang; Hao Hong; Timothy A Hacker; Hector F Valdovinos; James A Zagzebski; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2013-06-17       Impact factor: 4.939

Review 5.  PET/SPECT imaging of hindlimb ischemia: focusing on angiogenesis and blood flow.

Authors:  Hakan Orbay; Hao Hong; Yin Zhang; Weibo Cai
Journal:  Angiogenesis       Date:  2012-11-02       Impact factor: 9.596

Review 6.  Positron emission tomography imaging of atherosclerosis.

Authors:  Hakan Orbay; Hao Hong; Yin Zhang; Weibo Cai
Journal:  Theranostics       Date:  2013-11-02       Impact factor: 11.556

Review 7.  Advanced tracers in PET imaging of cardiovascular disease.

Authors:  Yesen Li; Wei Zhang; Hua Wu; Gang Liu
Journal:  Biomed Res Int       Date:  2014-10-15       Impact factor: 3.411

8.  Comparison of LDPI to SPECT perfusion imaging using (99m)Tc-sestamibi and (99m)Tc-pyrophosphate in a murine ischemic hind limb model of neovascularization.

Authors:  Geert Hendrikx; Mark H Vries; Matthias Bauwens; Marijke De Saint-Hubert; Allard Wagenaar; Joël Guillaume; Levinia Boonen; Mark J Post; Felix M Mottaghy
Journal:  EJNMMI Res       Date:  2016-05-27       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.